<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931862</url>
  </required_header>
  <id_info>
    <org_study_id>WVE-004-001</org_study_id>
    <nct_id>NCT04931862</nct_id>
  </id_info>
  <brief_title>Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)</brief_title>
  <acronym>FOCUS-C9</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wave Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wave Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the safety, tolerability, PK, and PD of intrathecal (IT) WVE-004 in adult patients&#xD;
      with C9orf72-associated ALS or FTD. To participate in the study, patients must have a&#xD;
      documented mutation (GGGGCC [G4C2] repeat expansion) in the first intronic region of the&#xD;
      C9orf72 gene and be diagnosed with ALS or FTD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Proportion of patients with adverse events (AEs)</measure>
    <time_frame>Period 1 Day 1 to Period 2 Week 24 (end of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Concentration of WVE-004 in cerebrospinal fluid (CSF)</measure>
    <time_frame>Period 1 Day 1 to Period 2 Week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Change from baseline in concentration of poly-GP levels in the CSF</measure>
    <time_frame>Period 1 Day 1 to Period 2 Week 24 (end of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>ALS</condition>
  <condition>FTD</condition>
  <arm_group>
    <arm_group_label>WVE-004 (Dose A) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-004 (Dose B) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-004 (Dose C) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-004 (Dose D) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WVE-004</intervention_name>
    <description>WVE-004 is a stereopure antisense oligonucleotide (ASO)</description>
    <arm_group_label>WVE-004 (Dose A) or placebo</arm_group_label>
    <arm_group_label>WVE-004 (Dose B) or placebo</arm_group_label>
    <arm_group_label>WVE-004 (Dose C) or placebo</arm_group_label>
    <arm_group_label>WVE-004 (Dose D) or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Artificial cerebrospinal fluid (aCSF)</description>
    <arm_group_label>WVE-004 (Dose A) or placebo</arm_group_label>
    <arm_group_label>WVE-004 (Dose B) or placebo</arm_group_label>
    <arm_group_label>WVE-004 (Dose C) or placebo</arm_group_label>
    <arm_group_label>WVE-004 (Dose D) or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ALS-specific: Diagnosis of ALS based on clinical manifestations.&#xD;
&#xD;
          2. ALS-specific: Clinically diagnosed possible, laboratory supported probable, probable,&#xD;
             or definite criteria for diagnosing ALS according to the World Federation of Neurology&#xD;
             revised El Escorial criteria.&#xD;
&#xD;
          3. ALS-specific: Patients receiving riluzole have been on a stable dose for a minimum of&#xD;
             30 days.&#xD;
&#xD;
          4. ALS-specific: Patients on edaravone have received a minimum of 1 cycle (28 days).&#xD;
&#xD;
          5. ALS-specific: Patients discontinuing riluzole or edaravone had the last dose&#xD;
             administered ≥1 month prior to Screening.&#xD;
&#xD;
          6. FTD-specific: Must have Global Clinical Dementia Rating - Frontotemporal Lobar&#xD;
             Degeneration (CDR® plus NACC FTLD) score of 0.5 or 1.&#xD;
&#xD;
          7. FTD-specific: Able to undergo periodic magnetic resonance imaging (MRI) of the brain.&#xD;
             Participants with mixed phenotype (ALS and FTD) need not undergo MRI if their ALS&#xD;
             symptoms prevent it.&#xD;
&#xD;
          8. Mixed-phenotype: Patients who are mixed phenotype (ALS and FTD) must meet both the&#xD;
             ALS-specific and FTD-specific criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant medical finding on the physical examination other than&#xD;
             C9orf72-associated ALS or FTD that, in the judgment of the Investigator, will make the&#xD;
             patient unsuitable for participation in, and/or completion of the trial procedures&#xD;
&#xD;
          2. Received any other investigational drug, biological agent, or device within 1 month or&#xD;
             5 half-lives of study agent, whichever is longer. Received an investigational&#xD;
             oligonucleotide, within the past 6 months or 5 half-lives of the drug, whichever is&#xD;
             longer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wave Life Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>855-215-4687</phone>
    <email>clinicaltrials@wavelifesci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Perron Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Merrilee Needham, MBBS, PhD, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center - Research Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simon Ducharme, MD, MSc, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James Hospital - Ireland</name>
      <address>
        <city>Dublin</city>
        <zip>D08 NHY1</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonard van den Berg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>WC2R 2LS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Shaw, MD, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Sheffield</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathon Cooper-Knock, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

